Abstract:Biomimetic nanoparticles aim to effectively emulate the behavior of either cells or exosomes. Leukocyte-based biomimetic nanoparticles, for instance, incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here we show that, while increasing the protein:lipid ratio to a maximum of 1:20 (w/w) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. Our combined use of a microfluidic, bottom-up approach and tuning of a key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve the treatment of inflammatory-based conditions through targeted nanodelivery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c05792?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c05792</a>.Effect of protein buffer on NP size (Figure S1). Native protein:lipid ratio (Figure S2). NP biomimetic markers, original WB membranes, and quantification (Figure S3). CD11b orientation studies revealed equal distribution of these cytoplasmic and exoplasmic parts (Figure S4). 21-day NP storage stability studies (Figure S5). Gating strategy for flow cytometry analysis of NP uptake (Figure S6). Non-inflamed and LPS-inflamed endothelial cells (Figure S7). In vitro association and uptake of biomimetic NP by non-inflamed murine endothelial cells (Figure S8). Percentage of positive cells in singlet gate of inflamed treated cells (Figure S9). Ex vivo imaging of left and right ears for biomimetic NP targeting in a LLI model (Figure S10). TNBC tumor luminescence quantification (Figure S11). In vivo biomimetic NP liver accumulation in TNBC model (Figure S12). Ex vivo imaging of TNBC tumors for NP accumulation after 24 h (Figure S13). Intravital microscopy for NP accumulation in inflamed vasculature of TNBC mice (Figure S14). Biomimetic NP accumulation in heart, lungs, and spleen in LLI model after 8 h (Figure S15). Biomimetic NP accumulation in liver, kidneys, and blood in LLI model after 8 h (Figure S16). Biomimetic NP accumulation in heart, lungs, spleen, liver, kidneys, and blood of TNBC tumor-bearing mice after 24 h (Figure S17). Image analysis of collagen fibers workflow (Figure S18) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c05792/suppl_file/nn0c05792_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Voluntary‐Opsonization‐Enabled Precision Nanomedicines for Inflammation Treatment

Neutrophil‐Based Delivery Systems for Nanotherapeutics

Complement Opsonized Protein Corona Activated by Precoated Immunoglobulin Enables Neutrophil-Hitchhiking for Rapid and Enhanced Drug Delivery for Acute Liver Failure Recovery

Neutrophil Membranes Coated, Antibiotic Agent Loaded Nanoparticles Targeting to the Lung Inflammation.

Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation

Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice

Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery

Inflammation-targeting Polymeric Nanoparticles Deliver Sparfloxacin and Tacrolimus for Combating Acute Lung Sepsis.

Simultaneously Controlling Inflammation and Infection by Smart Nanomedicine Responding to the Inflammatory Microenvironment

Versatile Protein Coronation Approach with Multiple Depleted Serum for Creating Biocompatible, Precision Nanomedicine.

Ph-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury

Nanotechnology Reinforced Neutrophil-Based Therapeutic Strategies for Inflammatory Diseases Therapy

Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses Through Selective Trapping of Endotoxins and Pro‐Inflammatory Cytokines

Tackling Severe Neutrophilic Inflammation in Airway Disorders with Functionalized Nanosheets.

Neutrophils and Macrophages as Targets for Development of Nanotherapeutics in Inflammatory Diseases

Nanotherapeutics: Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation (adv. Sci. 15/2019)

Inhalable nanocatalytic therapeutics for viral pneumonia

Co-delivery of Azithromycin and Ibuprofen by ROS-responsive Polymer Nanoparticles Synergistically Attenuates the Acute Lung Injury.

Chemotaxis‐guided Self‐propelled Macrophage Motor for Targeted Treatment of Acute Pneumonia

Cepharanthine loaded nanoparticles coated with macrophage membranes for lung inflammation therapy

Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles